Korro Bio: Promising Early Stage RNA Editing Company
Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...
Korro Bio (KRRO) Gets a Buy from Piper Sandler
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...
ETF Daily News6d
HC Wainwright Analysts Cut Earnings Estimates for Korro Bio
Read Our Latest Stock Report on KRRO Korro Bio Trading Up 1.1 % KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23 ...
Investing3d
Korro Bio reappoints CFO, names new principal accounting officer
Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company ...
Investing3d
Korro Bio reappoints CFO, names new principal accounting officer
Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company’s ...
Investing4d
KRRO stock touches 52-week low at $18.42 amid market challenges
In other recent news, Korro Bio has announced several significant developments. The company reported the completion of dosing for the first two healthy volunteer cohorts in its Phase 1/2 trial of KRRO ...